Mielodiszplasztikus szindróma (MDS): vizsgálatok itt: Kína
53 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 1/2. fázisNot yet taking people in KínaAnakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 66
- Run by
- Ruijin Hospital
See details and how to joinNCT07888348 - 1/2. fázisTaking peopleSonrotoclax Plus Azacitidine in Patients With MDS-IB2
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07885397 - 1. fázisTaking peoplePhase I Study of FXS0683 in the Treatment of Blood Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 228
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089 - 3. fázisTaking peopleLisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00 - 2. fázisTaking peopleVenetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 40
- Run by
- Beijing 302 Hospital
See details and how to joinNCT07238686 - 1. fázisTaking peopleA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Where
- Beijing, Guangdong, Hebei, Hubei
- Életkor
- 18 év to 75 év
- People
- 168
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06820268 - No phaseTaking peopleBrain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 323
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07578675 - 2. fázisTaking peopleAge-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 120
- Run by
- Peking University People's Hospital
See details and how to joinNCT07677306 - 1/2. fázisTaking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Lanzhou, Nanchang, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - 1. fázisTaking peopleA Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
- Where
- Nanchang, Suzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 198
- Run by
- Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT05641259 - No phaseTaking peopleVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
- Where
- Hangzhou
- Életkor
- 12 év to 60 év
- People
- 138
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07183878 - 1/2. fázisNot yet taking people in KínaA Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 92
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07591168 - 1. fázisTaking peopleICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Where
- Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Shengyang, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 266 worldwide
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06656494 - 1/2. fázisTaking peoplePBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 29
- Run by
- Chaser Therapeutics, Inc.
See details and how to joinNCT07761533 - No phaseTaking peopleLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Where
- Hainan
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054 - 3. fázisVisszavonvaA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin
- Életkor
- 18 év and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - No phaseTaking peopleHaplo-Cord HSCT for AML/MDS
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou
- Életkor
- 14 év to 60 év
- People
- 82
- Run by
- Fujian Medical University Union Hospital
See details and how to joinNCT07588360 - 2. fázisNot yet taking people in KínaChidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes
- Where
- Xiamen
- Életkor
- 60 év and over
- People
- 15
- Run by
- Zhongshan Hospital (Xiamen), Fudan University
See details and how to joinNCT07616336 - 2. fázisTaking peopleIvosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07607418 - 2. fázisTaking peopleRomiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
- Where
- Suzhou
- Életkor
- 18 év to 65 év
- People
- 66
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07400341 - No phaseTaking peopleA Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
- Where
- Suzhou
- Életkor
- 50 év and over
- People
- 30
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07500753 - 1/2. fázisTaking peopleAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Beijing Biotech
See details and how to joinNCT07523555 - 2. fázisNot yet taking people in KínaIFN-α in Relapse Prevention.
- Where
- Beijing
- Életkor
- 12 év to 65 év
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT07449286 - 2. fázisTaking peopleA Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 63
- Run by
- Kind Pharmaceuticals LLC
See details and how to joinNCT06304103 - No phaseTaking peoplePredictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
- Where
- Beijing, Wuhan, Zhengzhou
- Életkor
- 15 év to 70 év
- People
- 163
- Run by
- Peking University People's Hospital
See details and how to joinNCT06569095